VisionFirst Technologies

VisionFirst Technologies is a biotechnology company focused on developing first-in-class small molecule therapeutics for ophthalmic conditions, particularly ocular surface diseases. The company's lead program, VFT-001, targets the Wnt signaling pathway to promote the repair of the corneal epithelium and alleviate symptoms of dry eye disease. Spun off from the City University of Hong Kong, the company leverages a proprietary ocular drug discovery platform to identify novel treatments for vision-threatening disorders. VisionFirst is currently advancing its lead candidate through IND-enabling studies with a focus on addressing the inflammatory and degenerative components of chronic eye conditions. The firm has received support from the Hong Kong Science and Technology Parks Corporation and regional innovation funds to transition its academic research into clinical-stage assets.